[go: up one dir, main page]

BRPI0409258A - processo para resolução de aminas que são úteis para o tratamento de distúrbios associados com a sìndrome de resistência à insulina - Google Patents

processo para resolução de aminas que são úteis para o tratamento de distúrbios associados com a sìndrome de resistência à insulina

Info

Publication number
BRPI0409258A
BRPI0409258A BRPI0409258-9A BRPI0409258A BRPI0409258A BR PI0409258 A BRPI0409258 A BR PI0409258A BR PI0409258 A BRPI0409258 A BR PI0409258A BR PI0409258 A BRPI0409258 A BR PI0409258A
Authority
BR
Brazil
Prior art keywords
useful
insulin resistance
disorders associated
resistance syndrome
treating disorders
Prior art date
Application number
BRPI0409258-9A
Other languages
English (en)
Inventor
Gerard Moinet
Daniel Cravo
Thierry Passemar
Original Assignee
Merck Patent Ges Mit Beschaenk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Ges Mit Beschaenk filed Critical Merck Patent Ges Mit Beschaenk
Publication of BRPI0409258A publication Critical patent/BRPI0409258A/pt
Publication of BRPI0409258B1 publication Critical patent/BRPI0409258B1/pt
Publication of BRPI0409258B8 publication Critical patent/BRPI0409258B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/10—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"PROCESSO PARA RESOLUçãO DE AMINAS QUE SãO úTEIS PARA O TRATAMENTO DE DISTúRBIOS ASSOCIADOS COM A SìNDROME DE RESISTêNCIA à INSULINA". A presente invenção refere-se a um processo para resolver um composto de amina racêmica, derivado de dihidro-1,3,5-triazinas. A presente invenção refere-se também a enantiómeros de derivados de amina de dihidro-1,3,5-triazinas, e ao uso deles para a preparação de medicamentos, em particular, para o tratamento de diabete e malária.
BRPI0409258A 2003-04-10 2004-04-06 processo para resolução de compostos racêmicos BRPI0409258B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0304486 2003-04-10
FR0304486A FR2853650B1 (fr) 2003-04-10 2003-04-10 Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
PCT/EP2004/002476 WO2004089917A2 (en) 2003-04-10 2004-04-06 Process for resolving 2,4-diamino-3,6-dihydro-1,3,5-triazines, useful for the treatment of disorders associated with insulin resistance syndrome

Publications (3)

Publication Number Publication Date
BRPI0409258A true BRPI0409258A (pt) 2006-03-28
BRPI0409258B1 BRPI0409258B1 (pt) 2018-05-15
BRPI0409258B8 BRPI0409258B8 (pt) 2021-05-25

Family

ID=33041769

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409258A BRPI0409258B8 (pt) 2003-04-10 2004-04-06 processo para resolução de compostos racêmicos

Country Status (23)

Country Link
US (1) US7501511B2 (pt)
EP (1) EP1611111B1 (pt)
JP (1) JP4836778B2 (pt)
KR (1) KR101107665B1 (pt)
CN (1) CN100383130C (pt)
AR (1) AR044511A1 (pt)
AT (1) ATE425151T1 (pt)
AU (1) AU2004228125B2 (pt)
BR (1) BRPI0409258B8 (pt)
CA (1) CA2521879C (pt)
CY (1) CY1109609T1 (pt)
DE (1) DE602004019897D1 (pt)
DK (1) DK1611111T3 (pt)
ES (1) ES2321718T3 (pt)
FR (1) FR2853650B1 (pt)
MX (1) MXPA05010764A (pt)
PL (1) PL214955B1 (pt)
PT (1) PT1611111E (pt)
RU (1) RU2344131C2 (pt)
SI (1) SI1611111T1 (pt)
TW (1) TWI344464B (pt)
WO (1) WO2004089917A2 (pt)
ZA (1) ZA200509071B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
FR2896160B1 (fr) * 2006-01-13 2008-04-25 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agonistes du ppar alpha.
FR2896158B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase.
FR2896159B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
FR2896161B1 (fr) * 2006-01-13 2008-04-04 Merck Sante Soc Par Actions Si Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.
CN101468986B (zh) * 2007-12-26 2010-12-29 香港南北兄弟国际投资有限公司 一种二氢嘧啶消旋化合物的拆分方法
DE102008007314A1 (de) * 2008-02-02 2009-08-06 Merck Patent Gmbh Verfahren zur Herstellung von 3,6-Dihydro-1,3,5-triazinderivaten
AU2009250149B2 (en) * 2008-05-23 2013-05-23 Poxel Sas Process for the synthesis of 3,6-dihydro-1,3,5-triazine derivatives
WO2010012746A2 (en) * 2008-07-29 2010-02-04 Poxel Process of isolating enantiomer components from enantiomer mixtures by particle-size-controlled crystallization
DE102009014898A1 (de) * 2009-03-25 2010-09-30 Merck Patent Gmbh Prozess zur Enantiomerentrennung von 3,6-Dihydro-1,3,5-triazinderivaten
US8742102B2 (en) 2009-03-26 2014-06-03 Poxel Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization
FR2948027A1 (fr) 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
FR2948026B1 (fr) * 2009-07-17 2011-12-02 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine
TWI436768B (zh) 2010-06-09 2014-05-11 Poxel 第２型糖尿病之治療
JP5707489B2 (ja) * 2010-06-09 2015-04-30 ポクセル・エスアーエスＰｏｘｅｌｓａｓ １型糖尿病の処置
HUE026090T2 (en) * 2010-12-01 2016-05-30 Poxel Separation of enantiomeric triazine derivatives using tartaric acid
CN111163782A (zh) 2017-10-02 2020-05-15 普克塞尔公司 治疗射血分数保留型心力衰竭的方法
JP7635474B2 (ja) 2018-06-06 2025-02-26 プリスティーヌ・エスアーエス 慢性腎疾患を持つ糖尿病対象を治療する方法
EP3806828A1 (en) 2018-06-14 2021-04-21 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
WO2022152138A1 (zh) * 2021-01-15 2022-07-21 中国医药研究开发中心有限公司 稠和杂环类化合物及其制备方法和医药用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894027A (en) * 1973-07-31 1975-07-08 Merck & Co Inc Resolution of racemic reticuline and racemization of its enantiomers
JPS5414986A (en) * 1977-07-01 1979-02-03 Taiho Pharmaceutical Co Ltd Production of dihydrooss triazine derivative
JPH0436279A (ja) * 1990-06-01 1992-02-06 Kyowa Hakko Kogyo Co Ltd 光学活性なベンゾオキセピン誘導体の製造法
FR2665441B1 (fr) * 1990-07-31 1992-12-04 Sanofi Sa Derives de la n-sulfonyl indoline, leur preparation, les compositions pharmaceutiques en contenant.
US6013653A (en) * 1995-09-22 2000-01-11 Fujisawa Pharmaceuticals Co., Ltd. Processes for producing pyridoindole derivatives
MX9805870A (pt) * 1996-01-22 1999-01-31
JPH11193270A (ja) * 1997-12-26 1999-07-21 Koei Chem Co Ltd 光学活性１−メチル−３−ピペリジンメタノールの製造方法
JP4138928B2 (ja) * 1998-02-20 2008-08-27 山川薬品工業株式会社 Ｄ−アロイソロイシンの製造方法および製造の中間体
FR2775974B1 (fr) * 1998-03-16 2000-08-18 Rhodia Chimie Sa Procede de separation de diastereoisomeres d'une diphosphine et preparation de diphosphines optiquement actives
AU4698399A (en) * 1998-06-30 2000-01-17 Du Pont Pharmaceuticals Company 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors
JP2001199972A (ja) * 2000-01-20 2001-07-24 Eisai Co Ltd 光学活性ピペラジン誘導体の製造法
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
JP2002193933A (ja) * 2000-06-14 2002-07-10 Toray Ind Inc 光学活性ピペリジン誘導体またはその酸塩の製造方法
DE10042064A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Chinazoline, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10125131A1 (de) * 2001-05-23 2002-12-05 Bayer Ag Verfahren zur Spaltung des Methyl 4-(2-chlor-4-fluorphenyl)-2-(3,5-difluor-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrmidincarboxylat-Racemats
AR034759A1 (es) * 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram

Also Published As

Publication number Publication date
KR101107665B1 (ko) 2012-01-20
JP4836778B2 (ja) 2011-12-14
KR20050120791A (ko) 2005-12-23
JP2006522753A (ja) 2006-10-05
WO2004089917A2 (en) 2004-10-21
MXPA05010764A (es) 2005-12-12
PL214955B1 (pl) 2013-10-31
US7501511B2 (en) 2009-03-10
BRPI0409258B8 (pt) 2021-05-25
TW200504037A (en) 2005-02-01
DE602004019897D1 (de) 2009-04-23
EP1611111A2 (en) 2006-01-04
SI1611111T1 (sl) 2009-08-31
CN100383130C (zh) 2008-04-23
CA2521879A1 (en) 2004-10-21
AR044511A1 (es) 2005-09-14
TWI344464B (en) 2011-07-01
DK1611111T3 (da) 2009-05-18
RU2005134685A (ru) 2006-06-10
FR2853650B1 (fr) 2006-07-07
AU2004228125B2 (en) 2010-07-15
RU2344131C2 (ru) 2009-01-20
PL377833A1 (pl) 2006-02-20
ZA200509071B (en) 2007-04-25
BRPI0409258B1 (pt) 2018-05-15
CY1109609T1 (el) 2014-08-13
AU2004228125A1 (en) 2004-10-21
EP1611111B1 (en) 2009-03-11
HK1088002A1 (en) 2006-10-27
US20060223803A1 (en) 2006-10-05
ATE425151T1 (de) 2009-03-15
CN1771233A (zh) 2006-05-10
CA2521879C (en) 2013-01-08
PT1611111E (pt) 2009-06-18
WO2004089917A3 (en) 2004-12-23
ES2321718T3 (es) 2009-06-10
FR2853650A1 (fr) 2004-10-15

Similar Documents

Publication Publication Date Title
BRPI0409258A (pt) processo para resolução de aminas que são úteis para o tratamento de distúrbios associados com a sìndrome de resistência à insulina
BR0315047A (pt) Composto, composição fermacêutica que compreende o mesmo, processo para a preparação da composição farmacêutica, utilização dos compostos, método de tratamento e processo para a preparação do composto
BRPI0312398B8 (pt) derivado de 1,3-difenilprop-2-en-1-ona substituído, processo de preparação de compostos, composição farmacêutica e utilização de pelo menos um derivado de 1,3-difenilprop-2-en-1-ona substituído
BR0307576A (pt) Compostos; processo para a fabricação de compostos; composições farmacêuticas; método para o tratamento e/ou profilaxia de doenças associadas com o dpp iv; e uso de compostos
BRPI0517423A (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
BRPI0410760A (pt) compostos, processo para fabricação dos mesmos, composições farmacêuticas e uso deste compostos
BR0206433A (pt) Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um composto
BRPI0315143B8 (pt) composto, composição farmacêutica, e, uso de um composto
BR0315296A (pt) Derivados do ciclohexanol espirocìclicos
BR0210464A (pt) Composto, composição farmacêutica, processo para preparar um composto, e, uso de um composto
BR0009486B1 (pt) composto que compreende uma amida, composição farmacêutica que compreende esse composto, seu uso e processo para a preparação do mesmo.
BR0313160A (pt) Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
BRPI0515218A (pt) composto, composição farmacêutica, método para o tratamento de um mamìfero ou ser humano, método de uso do composto, novos intermediários, uso dos novos intermediários, processo para a preparação de um composto
BRPI0507903A (pt) derivados de quinazolina e composição farmacêutica compreendendo os mesmos
BRPI0900983A2 (pt) compostos de diometina, processo para sua preparação e composições farmacêuticas contendo os mesmos
BR0214559A (pt) sais de ácido succìnico do 5,8,14-triazatetraciclo [10.3.1.0<2,11>.0<4,9>]-hexadeca-2(11),3,5,7,9-penteno e suas composições farmacêuticas
BRPI0518898A2 (pt) composto, processo para sua preparaÇço, composiÇço farmacÊutica, mÉtodo para tratamento e uso do composto
BR0008297A (pt) Uso de 4,6-o-(benzilideno-d1) -d-glucopiranose, 4,6-o-benzilideno-l-glucopiranose, e/ou 4,6-o-(benzilideno-d1) -l-glucopiranose, ou um sal farmacêutico aceitável dos mesmos, derivado de benzaldeìdo composição farmacêutica, e, processo para a fabricação da mesma
BR0210650A (pt) Tablete, e, uso do mesmo
BR0110357A (pt) Sais bicìclicos e n-aciclados de aminas imidazo - 3 e imidazo -5
BRPI0411308A8 (pt) Composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto
BR0111897A (pt) Composto, método para tratar um indivìduo afligido por alguns distúrbios dos sistemas nervosos periférico e central, composição farmacêutica, e, uso de um composto
BRPI0417469B8 (pt) bifenil carboxamidas substituídas com n-aril piperidina, composição farmacêutica que os compreende e processo de preparação destes
BR0012754A (pt) Poliaminas que apresentam grupos uréia, processos para a sua preparação, bem como seu emprego como endurecedores para resinas epóxido
BR9705456A (pt) Compostos heterocìclicos, processo de aminometila para sua preparação e composições farmacêuticas que os contêm.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: POXEL S.A.S (FR)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/04/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2665 DE 01-02-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.